Miyairi S, Shimada H, Morita H, Awata N, Goto J, Nambara T
Pharmaceutical Institute, Tohoku University, Sendai, Japan.
J Pharm Biomed Anal. 1993 Jun;11(6):469-76. doi: 10.1016/0731-7085(93)80159-x.
A specific enzyme immunoassay (EIA) has been developed for 4-hydroxy-2-(4-methylphenyl)benzothiazole (KB-2714) (1), an active metabolite of 4-acetoxy-2-(4-methylphenyl)benzothiazole (KB-2683) (2) which is a promising anti-rheumatic agent. The EIA was based upon antiserum elicited against 5-(2-carboxyphenylazo)-4-hydroxy-2-(4-methylphenyl)benzothiazole (3)-bovine serum albumin conjugate and beta-galactosidase-labelled 5-amino-4-hydroxy-2-(4-methylphenyl)benzothiazole (5). The sensitivity of the EIA was significantly improved by the utilization of a bridge heterologous combination system. An appropriate dose-response curve of EIA for 4-hydroxy-2-(4-methylphenyl)benzothiazole was obtained in the range of 10 pg tube-1-20 ng tube-1. The specificity of EIA proved to be satisfactory in terms of cross-reactivities to 14 benzothiazole-related compounds including glucuronic acid and sulphuric acid conjugates. The proposed method was evaluated to be useful for the determination of 1 in urine and plasma with acceptable recovery and inter- and intra-assay precision.
已开发出一种针对4-羟基-2-(4-甲基苯基)苯并噻唑(KB - 2714)(1)的特异性酶免疫测定法(EIA),KB - 2714是4-乙酰氧基-2-(4-甲基苯基)苯并噻唑(KB - 2683)(2)的活性代谢产物,而KB - 2683是一种有前景的抗风湿药物。该酶免疫测定法基于针对5-(2-羧基苯基偶氮)-4-羟基-2-(4-甲基苯基)苯并噻唑(3)-牛血清白蛋白偶联物和β-半乳糖苷酶标记的5-氨基-4-羟基-2-(4-甲基苯基)苯并噻唑(5)产生的抗血清。通过使用桥联异源组合系统,显著提高了酶免疫测定法的灵敏度。在10 pg/管 - 20 ng/管的范围内获得了4-羟基-2-(4-甲基苯基)苯并噻唑的合适酶免疫测定剂量反应曲线。就与包括葡萄糖醛酸和硫酸共轭物在内的14种苯并噻唑相关化合物的交叉反应性而言,酶免疫测定法的特异性被证明是令人满意的。经评估,所提出的方法可用于测定尿液和血浆中的1,回收率以及批间和批内精密度均可接受。